Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imraldi

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

AbbVie’s HIV therapy Kaletra fails to show efficacy in COVID-19

Drug failed to improved condition of hospitalised COVID-19 patients

- PMLiVE

FDA sets November date for expert panel review of Biogen’s aducanumab

Advisory committee will review biologics license application for controversial therapy

- PMLiVE

AbbVie signs immunotherapy pact with I-Mab worth $2bn

Focus of deal is anti-CD47 monoclonal antibody lemzoparlimab

- PMLiVE

AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML

Data from the trial has been published in the New England Journal of Medicine

- PMLiVE

Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month

Monoclonal antibody has neutralised SARS-CoV-2 virus in vitro

- PMLiVE

Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Drug could become first treatment to reduce clinical decline in Alzheimer's

- PMLiVE

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links